Resveratrol, through NF‐Y/p53/Sin3/HDAC1 complex phosphorylation, inhibits estrogen receptor α gene expression via p38MAPK/CK2 signaling in human breast cancer cells

Agents to counteract acquired resistance to hormonal therapy for breast cancer would substantially enhance the long‐term benefits of hormonal therapy. In the present study, we demonstrate how resveratrol (Res) inhibits human breast cancer cell proliferation, including MCF‐7 tamoxifen‐resistant cells (IC50 values for viability were in the 30–45 μM range). We show that Res, through p38MAPK phosphorylation, causes induction of p53, which recruits at the estrogen receptor α (ERα) proximal promoter, leading to an inhibition of ERα expression in terms of mRNA and protein content. These events appear specifically p53 dependent, since they are drastically abrogated with p53‐targeting siRNA. Coimmunoprecipitation assay showed specific interaction between p53, the Sin3A corepressor, and histone deacetylase 1 (HDAC1), which was phosphorylated. The enhancement of the tripartite complex p53/Sin3A/HDAC1, together with NF‐Y on Res treatment, was confirmed by chromatin immunoprecipitation analyses, with a concomitant release of Sp1 and RNA polymerase II, thereby inhibiting the cell transcriptional machinery. The persistence of such effects in MCF‐7 tamoxifen‐resistant cells at a higher extent than parental MCF‐7 cells addresses how Res may be considered a useful pharmacological tool to be exploited in the adjuvant settings for treatment of breast cancer developing hormonal resistance.—De Amicis, F., Giordano, F., Vivacqua, A., Pellegrino, M., Panno, M. L., Tramontano, D., Fuqua, S. A. W., Andò, S. Resveratrol, through NF‐Y/p53/Sin3/HDAC1 complex phosphorylation, inhibits estrogen receptor α gene expression via p38MAPK/CK2 signaling in human breast cancer cells. FASEB J. 25, 3695–3707 (2011). www.fasebj.org

[1]  B. Vogelstein,et al.  Suppression of human colorectal carcinoma cell growth by wild-type p53. , 1990, Science.

[2]  K. Matsumoto,et al.  Phosphorylation of the retinoblastoma protein by cdk2. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[3]  R. Sutherland,et al.  Circumvention of tamoxifen resistance by the pure anti‐estrogen ICI 182, 780 , 1993, International journal of cancer.

[4]  R. Lupu,et al.  Bidirectional interactions between the estrogen receptor and the c‐erbB‐2 signaling pathways: Heregulin inhibits estrogenic effects in breast cancer cells , 1995, International journal of cancer.

[5]  Daniel Metzger,et al.  Activation of the Estrogen Receptor Through Phosphorylation by Mitogen-Activated Protein Kinase , 1995, Science.

[6]  D. Picard,et al.  Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation. , 1996, The EMBO journal.

[7]  R. Hansen,et al.  Auto-regulation of the estrogen receptor promoter , 1997, The Journal of Steroid Biochemistry and Molecular Biology.

[8]  E. Surmacz,et al.  Tamoxifen interferes with the insulin-like growth factor I receptor (IGF-IR) signaling pathway in breast cancer cells. , 1997, Cancer research.

[9]  M. Sporn,et al.  Recent advances in chemoprevention of cancer. , 1997, Science.

[10]  S. Cheng,et al.  The tumor suppressor p53 is a negative regulator of estrogen receptor signaling pathways. , 1997, Biochemical and biophysical research communications.

[11]  B. O’Malley,et al.  Coactivator and corepressor regulation of the agonist/antagonist activity of the mixed antiestrogen, 4-hydroxytamoxifen. , 1997, Molecular endocrinology.

[12]  M. Fontecave,et al.  Resveratrol, a remarkable inhibitor of ribonucleotide reductase , 1998, FEBS letters.

[13]  H. Ciolino,et al.  Inhibition of aryl hydrocarbon-induced cytochrome P-450 1A1 enzyme activity and CYP1A1 expression by resveratrol. , 1999, Molecular pharmacology.

[14]  G. Condorelli,et al.  The B Subunit of the CAAT-binding Factor NFY Binds the Central Segment of the Co-activator p300* , 1999, The Journal of Biological Chemistry.

[15]  Z. Darżynkiewicz,et al.  Cell cycle effects and control of gene expression by resveratrol in human breast carcinoma cell lines with different metastatic potentials. , 1999, International journal of oncology.

[16]  G. Liu,et al.  p53 down-regulates ER-responsive genes by interfering with the binding of ER to ERE. , 1999, Biochemical and biophysical research communications.

[17]  J. Pezzuto,et al.  Cancer Chemopreventive Activity of Resveratrol , 2002, Drugs under experimental and clinical research.

[18]  Jen-kun Lin,et al.  Suppression of nitric oxide synthase and the down‐regulation of the activation of NFκB in macrophages by resveratrol , 1999, British journal of pharmacology.

[19]  Weiya Ma,et al.  Resveratrol suppresses cell transformation and induces apoptosis through a p53-dependent pathway. , 1999, Carcinogenesis.

[20]  Jianbiao Zheng,et al.  Inhibition of mitochondrial proton F0F1‐ATPase/ATP synthase by polyphenolic phytochemicals , 2000, British journal of pharmacology.

[21]  C. Klinge,et al.  Resveratrol acts as a mixed agonist/antagonist for estrogen receptors alpha and beta. , 2000, Endocrinology.

[22]  C. Klinge,et al.  Printed in U.S.A. Copyright © 2000 by The Endocrine Society Resveratrol Acts as a Mixed Agonist/Antagonist for , 2022 .

[23]  K. Christman,et al.  Effects of resveratrol on the autophosphorylation of phorbol ester-responsive protein kinases: inhibition of protein kinase D but not protein kinase C isozyme autophosphorylation. , 2000, Biochemical pharmacology.

[24]  Kristen Jepsen,et al.  Combinatorial Roles of the Nuclear Receptor Corepressor in Transcription and Development , 2000, Cell.

[25]  M. Murphy,et al.  The Corepressor mSin3a Interacts with the Proline-Rich Domain of p53 and Protects p53 from Proteasome-Mediated Degradation , 2001, Molecular and Cellular Biology.

[26]  J. Reiffers,et al.  Resveratrol inhibits the growth and induces the apoptosis of both normal and leukemic hematopoietic cells. , 2002, Carcinogenesis.

[27]  S. Hilsenbeck,et al.  Sp1 is essential for estrogen receptor alpha gene transcription. , 2002, The Journal of steroid biochemistry and molecular biology.

[28]  S. Hilsenbeck,et al.  Sp1 is essential for estrogen receptor α gene transcription , 2002, The Journal of Steroid Biochemistry and Molecular Biology.

[29]  Patrick Diel,et al.  Tissue-specific estrogenic response and molecular mechanisms. , 2002, Toxicology letters.

[30]  S. Benchimol,et al.  Transcriptional repression mediated by the p53 tumour suppressor , 2003, Cell Death and Differentiation.

[31]  L. Donehower,et al.  Activities of wildtype and mutant p53 in suppression of homologous recombination as measured by a retroviral vector system. , 2003, Mutation research.

[32]  F. Scarlatti,et al.  The FASEB Journal express article 10.1096/fj.03-0292fje. Published online October 16, 2003. Resveratrol induces growth inhibition and apoptosis in metastatic breast cancer cells via de novo ceramide signaling , 2022 .

[33]  R. Nicholson,et al.  Oestrogen Receptor-Mediated Modulation of the EGFR/MAPK Pathway in Tamoxifen-Resistant MCF-7 Cells , 2003, Breast Cancer Research and Treatment.

[34]  E. Diamandis,et al.  Quantitative analysis of mutant p53 protein in breast tumor cytosols and study of its association with other biochemical prognostic indicators in breast cancer , 2004, Breast Cancer Research and Treatment.

[35]  W. McGuire,et al.  Measurement of steroid hormone receptors in breast cancer patients on tamoxifen , 2004, Breast Cancer Research and Treatment.

[36]  C. Kedinger,et al.  A p38 inhibitor allows to dissociate differentiation and apoptotic processes triggered upon LIF withdrawal in mouse embryonic stem cells , 2004, Cell Death and Differentiation.

[37]  Bert W O'Malley,et al.  Coregulator function: a key to understanding tissue specificity of selective receptor modulators. , 2004, Endocrine reviews.

[38]  A. Fornace,et al.  Casein Kinase 2- and Protein Kinase A-regulated Adenomatous Polyposis Coli and β-Catenin Cellular Localization Is Dependent on p38 MAPK* , 2005, Journal of Biological Chemistry.

[39]  L. Chodosh,et al.  Deregulated estrogen receptor alpha expression in mammary epithelial cells of transgenic mice results in the development of ductal carcinoma in situ. , 2005, Cancer research.

[40]  A. Gartel,et al.  Lost in transcription: p21 repression, mechanisms, and consequences. , 2005, Cancer research.

[41]  R. Mantovani,et al.  Direct p53 Transcriptional Repression: In Vivo Analysis of CCAAT-Containing G2/M Promoters , 2005, Molecular and Cellular Biology.

[42]  R. Kumar,et al.  Long-term estradiol deprivation in breast cancer cells up-regulates growth factor signaling and enhances estrogen sensitivity. , 2005, Endocrine-related cancer.

[43]  Hung-Yun Lin,et al.  Integrin αVβ3 contains a receptor site for resveratrol , 2006 .

[44]  S. Hilsenbeck,et al.  Elevated expression of mitogen-activated protein kinase phosphatase 3 in breast tumors: a mechanism of tamoxifen resistance. , 2006, Cancer research.

[45]  Hung-Yun Lin,et al.  Integrin alphaVbeta3 contains a receptor site for resveratrol. , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[46]  C. Prives,et al.  Transcriptional regulation by p53: one protein, many possibilities , 2006, Cell Death and Differentiation.

[47]  J. Davie,et al.  Differential Distribution of Unmodified and Phosphorylated Histone Deacetylase 2 in Chromatin* , 2007, Journal of Biological Chemistry.

[48]  M. Cammer,et al.  Estrogen and resveratrol regulate Rac and Cdc42 signaling to the actin cytoskeleton of metastatic breast cancer cells. , 2007, Neoplasia.

[49]  G. Sauter,et al.  Estrogen receptor alpha (ESR1) gene amplification is frequent in breast cancer , 2007, Nature Genetics.

[50]  B. O’Malley,et al.  Selective estrogen-receptor modulators and antihormonal resistance in breast cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[51]  L. Donehower,et al.  Aging-associated truncated form of p53 interacts with wild-type p53 and alters p53 stability, localization, and activity , 2007, Mechanisms of Ageing and Development.

[52]  I. Morita,et al.  Protein kinase CK2 is a key activator of histone deacetylase in hypoxia‐associated tumors , 2008, International journal of cancer.

[53]  S. Andò,et al.  Evidence that bergapten, independently of its photoactivation, enhances p53 gene expression and induces apoptosis in human breast cancer cells. , 2009, Current cancer drug targets.

[54]  Jie Tian,et al.  Transcriptional regulation of estrogen receptor-alpha by p53 in human breast cancer cells. , 2009, Cancer research.

[55]  S. Fuqua,et al.  Growth factor-induced resistance to tamoxifen is associated with a mutation of estrogen receptor α and its phosphorylation at serine 305 , 2009, Breast Cancer Research and Treatment.

[56]  S. Fuqua,et al.  G protein-coupled receptor 30 expression is up-regulated by EGF and TGF alpha in estrogen receptor alpha-positive cancer cells. , 2009, Molecular endocrinology.

[57]  I. Barone,et al.  Progesterone receptor B recruits a repressor complex to a half-PRE site of the estrogen receptor alpha gene promoter. , 2009, Molecular endocrinology.

[58]  D. Das,et al.  Dose-Dependency of Resveratrol in Providing Health Benefits , 2010, Dose-response : a publication of International Hormesis Society.